首页> 外文期刊>Leukemia Research Reports >Targeted therapy for medullary and extramedullary relapse of FLT3-ITD acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation
【24h】

Targeted therapy for medullary and extramedullary relapse of FLT3-ITD acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation

机译:针对性造血干细胞移植后FLT3-ITD急性髓性白血病的髓质和髓外复发的靶向治疗

获取原文
       

摘要

We report a case with extramedullary tumors affecting the supraclavicular region that presented as a relapse of acute myeloid leukemia (AML) with FLT3-ITD mutation after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Treatment with gilteritinib resulted in remarkable response with disappearance of both the medullary and extramedullary tumors. Subsequently, a 2nd allo-HSCT was performed in an attempt to cure his AML and complete molecular response has been sustained with gilteritinib resumption without worsening GVHD. Targeted therapy with gilteritinib for medullary and extramedullary relapse ofFLT3-ITDAML could be effective and suitable as a bridging therapy for allo-HSCT.
机译:我们向异常造血干细胞移植(Allo-HSCT)后,患有影响急性髓性白血病(AML)的急性髓性白血病(AML)的急性髓性白血病(AML)复发的蛋白质。 用Gilteritinib治疗导致髓间质和髓外肿瘤的消失具有显着反应。 随后,进行第二种Allo-HSCT以试图治愈他的AML,并且通过Gilteritinib恢复来维持完全分子反应而不会恶化GVHD。 针对Gilteritinib进行髓质和髓外复发的靶向治疗oflt3-ITDAML可能是有效的,适合作为Allo-HSCT的桥接治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号